Category Archives: Press Releases

Quorum Innovations Demonstrates Human Microbiome Modulation

USPTO 9,706,778 PATENT ALLOWANCE FOR MATERIALS & METHODS FOR IMPROVING IMMUNE RESPONSES & SKIN OR MUCOSAL BARRIER

SARASOTA, Fla., Aug. 30, 2017 /PRNewswire/ — Quorum Innovations today announced a major advancement in improving immune responses and skin/mucosal barrier by modulating the human microbiome. Utilizing a proprietary Lactobacillus fermentum , native to the human microbiota, Quorum has demonstrated the growth of commensal bacteria while inhibiting the growth of methicillin-resistant Staphylococcus aureus (MRSA).

Learn more about Quorum Innovations at www.quoruminnovations.com

Quorum Innovations’ patent identifies the compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Quorum’s invention provides pharmaceutical and cosmetic compositions, and the methods comprising a strain of Lactobacillus fermentum bacterium native to human microbiota and capable of growing in biofilm phenotype.

Quorum is pleased that the USPTO has again recognized the novelty and importance of the human microbiome which is the cornerstone of this patent. Quorum has demonstrated the unique ability to modulate the human microbiome. Including skin and mucosal barrier function such as the nose, esophagus, and gut. Quorum’s Qi-601 promotes the growth of health-promoting commensal bacteria while inhibiting the growth of methicillin-resistant Staphylococcus aureus (MRSA). Quorum Innovations has successfully isolated a unique series of bacterial-derived bioactive compounds. They protect the human microbiome by simultaneously decreasing disease-causing bacteria while defending and increasing health-promoting bacteria. Quorum has named these compounds – ProBiomic™ Therapeutics.  Unlike other products on the market today, Quorum Bioactives are native to the human microbiome itself, and do not derive from foreign sources such as dirt, exotic plants, or animals.  They are grown in biofilm form and then processed such that the bioactive compounds contain no live bacteria. Quorum’s ProBiomic™ is stable in many vehicles, including alcohol, lipids, and aqueous. Quorum Innovations ProBiomic™ technology can currently be found in Quorum Innovation’s skin care line – BioEsse (www.bioesseprobiotics.com)

About Quorum Innovations

Dr. Nicholas Monsul, MD,  CEO,  and Dr. Eva Berkes, MD, Chief Science Officer, founded Quorum Innovations in 2011.  Quorum Innovation’s next generation probiotics – Probiomics® are being developed for application in skin care, food/beverages/ supplements, hygiene, and new drug candidates.

If you would like more information about this topic, please contact Dirk Henson at (dhenson@quoruminnovations.com)

U.S. Patent Allowance For Methods Of Identifying A Biologically-Active Composition From A Biofilm

quorum-innovations

Quorum Innovations Advances Human Microbiome Program 

PRNewswire/Sarasota, FL, October 27, 2016– Quorum Innovations today announced a major milestone that includes a drug discovery platform to advance the introduction of new treatments for skin, GI, inflammatory and metabolic conditions utilizing human microbiome therapeutics.

Quorum is pleased that the USPTO has recognized the novelty and importance of this drug discovery process which is the cornerstone of this patent. Quorum expects to accelerate development in a new class of therapeutics utilizing the human microbiome. Quorum Innovations has successfully isolated a unique series of bacterial derived bioactive compounds. They protect the human microbiome by simultaneously decreasing disease-causing bacteria while defending and increasing health-promoting bacteria. Quorum has named these compounds – ProBiomic™ Therapeutics.  Unlike other products on the market today, Quorum bioactives are also sourced from the human microbiome itself, not from foreign sources such as dirt, exotic plants, or animals.  It is grown in biofilm form and then processed such that the bioactive compounds contain no live bacteria. Quorum Innovations ProBiomic™ technology can currently be found in Quorum Innovation’s skin care line – BioEsse (www.bioesseprobiotics.com)

Other unique activities of Quorum Innovations’ ProBiomicTM   Therapeutics include: reduction of inflammation, promotion of innate immune defenses, upregulation of key tissue structural proteins such as filaggrin in human skin and esophagus, and modulation of critical metabolic control genes. Furthermore, bioactivities and can be formulated in multiple vehicles, including alcohol, aqueous and lipid, have been tested and found to be stable. Unlike most other bacteria which require being kept alive to maintain effect, Quorum Innovation’s bioactives maintains activity even after heat sterilization. These characteristics enable use in a broad range of applications, from direct-to-consumer to pharmaceutical products.

 

 

About Quorum Innovations

Dr. Nicholas Monsul, MD, CEO, and Dr. Eva Berkes, MD, Chief Science Officer, founded Quorum Innovations in 2011.  Quorum Innovation’s new drug candidates are extracted from the human microbiome. This creates a new era in immunology and drug discovery.  Once delivered, like native human microbiota in healthy individuals, Quorum Innovation’s ProBiomicTM  Therapeutics act like microbiome-based software to direct human cells to express particular proteins within target tissues.  By matching the particular ProBiomicTM   Therapeutic   to the desired protein effect in the chosen organ of interest, our new human microbiome-based therapeutics have the power to regulate human and human microbiomial physiology like no other therapeutic system today.

Emerging research on various types of inflammation indicate direct links between many clinical conditions and a dysbiotic or abnormal microbiome.  Skin inflammation causes skin barrier compromise, leading to conditions such as atopic dermatitis, psoriasis, acne and rosacea.  Pharmaceutical and personal care industries are seeking better ways to prevent and treat chronic skin disorders and other inflammatory conditions by addressing the underlying microbiome imbalances associated with these conditions.

Quorum Innovations’ ProBiomic™ Therapeutics have demonstrated proof of concept in ex-vivo, in vitro, and initial human clinical testing.  Pre-clinical and clinical models show that these human microbiome-derived therapeutics modulate the innate immune system by rebalancing the microbiome to: 1) reduce skin inflammation as measured by IL-1a levels, 2) enhance the diversity of the protective commensal population, 3) disperse and facilitate the kill of pathogens such as MRSA and Pseudomonas, 4) prevent adhesion of new pathogens, and 5) increase production of filaggrin and other critical structural proteins. The ability of  Quorum Innovations’ ProBiomic™ Therapeutics to delived these activities to local tissues results in effective, safe treatment with minimal systemic exposure.

QUORUM INNOVATIONS ANNOUNCES AVAILABILITY OF HUMAN MICROBIOME THERAPEUTICS TO TREAT COMMON SKIN CONDITIONS AND METABOLIC DISORDERS

Quorum Innovations has successfully isolated LfQi6 from the human host. Demonstrating strong biofilm formations. Bioactives from LfQi6 have novel bimodal biofilm modulation. Quorum Innovation’s Probiomic Therapeutics™ inhibit and detach pathogenic biofilm while enhancing commensal resident biofilm. Reducing inflammation, promoting inherent defense barriers, and immune functions by upregulating the expression of essential homeostatic protein and filaggrin in human tissue.

Quorum Innovations has demonstrated stability of the LfQi6 Probiomic TherapiesÒ in alcohol, aqueous, and lipid vehicles. Providing for a wide range of applications.

Dr. Nicholas Monsul, MD – CEO and Dr. Eva Berkes, MD – Chief Medical Officer founded Quorum Innovations in 2011.  “Quorum Innovation’s new drug candidates are extracted from the human microbiome in a “vertical advance” that creates a new era in immunology by helping to overcome microbial resistance to antibiotics.  Once delivered, like native human microbiota in healthy individuals, Quorum Innovation’s Probiomic TherapeuticsTM   act like microbiome-based software to direct human cells to express particular proteins within target tissues.  By matching the particular Probiomic TherapeuticTM   to the desired protein effect in the chosen organ of interest, our new human microbiome-based therapeutics have the power to regulate human and human microbiomial physiology like no other therapeutic system today.”

Emerging research on various types of inflammation indicate direct links to many clinical conditions and a dysbiotic or abnormal microbiome.  When the skin is inflamed, its barrier functions become compromised leading to conditions such as atopic dermatitis, psoriasis, acne and rosacea.  This has led the pharmaceutical and personal care industries to seek better ways to prevent and address skin inflammation and chronic inflammatory disorders.

Quorum’s bio-extracts, have demonstrated proof of concept in ex-vivo, in-vitro, and initial human clinical testing.  Pre-clinical and clinical models show that these bio-extracts modulate the innate immune system by rebalancing the microbiome to: 1) reduce skin inflammation as measured by IL-1a levels, 2) enhance the diversity of the protective commensal population, 3) disperse and facilitate the kill of pathogenic biofilms such as MRSA and pseudomonas, 4) prevent formation of new pathogenic biofilms, and 5) up-regulate filaggrin. This results in effective treatment with minimal systemic exposure.

Quorum Innovations announces “A Novel Human-Derived Probiotic Extract with Anti-MRSA Biofilm Therapeutic Effect” at American College of Asthma Allergy and Immunology

Berkes EA, Subhadra B, Henson M, Krier J, Monsul N

Introduction: Skin health, particularly in patients with atopic dermatitis, includes homeostasis among the microbes comprising the dermatologic microbiome. Biofilms are the surface-colonizing form of life preferred by most microbes, including pathogens, and grow on most surfaces. Commensals may help support a healthy skin barrier by inhibiting pathogenic biofilms such as methicillin resistant Staphylococcus aureus (MRSA). Using a patent-pending bio-extract from a novel probiotic human commensal organism, we defined MRSA anti- biofilm activities of potential clinical relevance in the prevention and treatment of MRSA biofilms.

Methods: Using a 96-well biofilm microplate assay, proprietary bio-extracts were tested against clinical MRSA isolates for 2 anti-biofilm activities: anti-biofilm adhesion and detachment of MRSA biofilm. Both biofilm activities were compared against vancomycin, meropenem or both.

Results: Anti-adhesion: The proprietary bio-extract was 2-3x more effective than antibiotic controls, with 35% anti-adhesion at 0.01 mg/ml, 50% at 0.05 mg/ml, 58% at 0.1 mg/ml, 85% at 0.5 mg/ml and 90% at 1 mg/ml when compared against untreated growth control. Biofilm detachment: The proprietary bio-extract was up to 10 times more effective than antibiotic controls: 0.05 mg/ml detached 50% of MRSA biofilm, whereas vancomycin and meropenem both detached approximately 5%. Unlike the anti-adhesive assay, there was no apparent dose-dependence, as percent detachment declined as bio-extract concentration increased. Lack of dose- dependence may reflect non-metabolic mechanisms of action and/or brief application time.

Conclusion: The novel human-probiotic derived bio-extract could synergistically and safely treat and prevent MRSA biofilms present on biologic surfaces such as the skin in clinically relevant chronic disease states of the skin, such as atopic dermatitis. Skin of AD patients is diffusely colonized by Staphylococcus aureus (S. aureus) and methicillin-resistant Staphylococcus aureus (MRSA). Increased burden of these microbes have been shown to be associated with acute exacerbations; chronically, presence of these microbes are associated with inflammation, decreased skin immune defense, a skew towards an allergic milieau and a weakened skin barrier. Recently, MRSA biofilms have been shown to be a key factor in the persistence of these microbes in AD patients. Treatments such as antibiotics and bleach baths have been used but carry their own challenges, including antibiotic resistance, skin microbiome derangement, cost, further skin barrier damage, exposure to oxidants and patient/family treatment adherence. This novel, human probiotic-derived bio-extract may be able to overcome these challenges while avoiding additional medication, especially antibiotic exposure, by presenting a novel and naturally-derived means to safely and topically prevent and reduce MRSA biofilm burden in the large atopic dermatitis population.

View on Medscape